RESUMO
BACKGROUND: The recommendations in guidelines are based on evidence; however, there is a gap between recommendations and clinical practice. OBJECTIVE: To describe the practice of prescribing evidence-based treatments for patients with acute coronary syndrome in Brazil. METHODS: This study carried out a subanalysis of the ACCEPT registry, assessing epidemiological data and the prescription rate of acetylsalicylic acid, p2y12 inhibitors, antithrombotic drugs, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (IAT1RB), and statins. In addition, the quality of myocardial reperfusion in ST-segment elevation myocardial infarction was evaluated. RESULTS: This study assessed 2,453 patients. The prescription rates of acetylsalicylic acid, p2y12 inhibitors, antithrombotic drugs, beta-blockers, angiotensin-converting enzyme inhibitors/IAT1RB, and statins were as follows: in 24 hours - 97.6%, 89.5%, 89.1%, 80.2%, 67.9% and 90.6%; and at six months - 89.3%, 53.6%, 0%, 74.4%, 57.6% and 85.4%, respectively. Regarding ST-segment elevation myocardial infarction, only 35.9% and 25.3% of the patients underwent primary angioplasty and thrombolysis, respectively, within the recommended times. CONCLUSION: This registry showed high initial prescription rates of antiplatelet drugs, antithrombotic drugs, and statins, and lower prescription rates of beta-blockers and angiotensin-converting enzyme inhibitors/IAT1RB. Independently of the class, the use of all drugs decreased by six months. Most patients with ST-segment elevation myocardial infarction did not undergo myocardial reperfusion within the time recommended.
Assuntos
Síndrome Coronariana Aguda/tratamento farmacológico , Prescrições de Medicamentos/estatística & dados numéricos , Medicina Baseada em Evidências/normas , Guias de Prática Clínica como Assunto/normas , Antagonistas Adrenérgicos beta/uso terapêutico , Idoso , Análise de Variância , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Aspirina/uso terapêutico , Brasil , Feminino , Fibrinolíticos/uso terapêutico , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/tratamento farmacológico , Reperfusão Miocárdica , Inibidores da Agregação Plaquetária/uso terapêutico , Antagonistas do Receptor Purinérgico P2Y/uso terapêutico , Fatores de Tempo , Resultado do TratamentoRESUMO
Fundamento: As diretrizes baseiam-se em evidências para pautar suas recomendações; apesar disso, há uma lacuna entre o recomendado e a prática clínica. Objetivo: Descrever a prática de prescrição de tratamentos com indicação baseada em diretrizes para pacientes com síndrome coronariana aguda no Brasil. Métodos: Foi realizada uma subanálise do registro ACCEPT, na qual foram avaliados os dados epidemiológicos e a taxa de prescrição de ácido acetilsalicílico, inibidores P2Y12, antitrombóticos, betabloqueadores, inibidores da enzima conversora de angiotensina/bloqueadores AT1 e estatinas. Além disso, avaliou-se a qualidade da reperfusão coronariana no infarto com supradesnivelamento do segmento ST. Resultados: Foram avaliados 2.453 pacientes. As taxas de prescrição de ácido acetilsalicílico, inibidores de P2Y12, antitrombóticos, betabloqueadores, inibidores da enzima conversora de angiotensina/bloqueadores AT1 e estatinas foram, respectivamente, de 97,6%, 89,5%, 89,1, 80,2%, 67,9%, 90,6%, em 24 horas, e, respectivamente, de 89,3%, 53,6, 0%, 74,4%, 57,6%, 85,4%, em 6 meses. Com relação ao infarto com supradesnivelamento do segmento ST, somente 35,9% e 25,3% dos pacientes foram submetidos a angioplastia primária e trombólise, respectivamente, nos tempos recomendados. Conclusão: Este registro mostrou altas taxas de prescrição inicial de antiplaquetários, antitrombóticos e estatina, bem como taxas mais baixas de betabloqueadores e de inibidores da enzima conversora de angiotensina/bloqueadores AT1. Independentemente da classe, todos apresentaram queda do uso aos 6 meses. A maioria dos pacientes com infarto com supradesnivelamento do segmento ST não foi submetida a reperfusão coronariana no tempo recomendado. .
Background: The recommendations in guidelines are based on evidence; however, there is a gap between recommendations and clinical practice. Objective: To describe the practice of prescribing evidence-based treatments for patients with acute coronary syndrome in Brazil. Methods: This study carried out a subanalysis of the ACCEPT registry, assessing epidemiological data and the prescription rate of acetylsalicylic acid, p2y12 inhibitors, antithrombotic drugs, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (IAT1RB), and statins. In addition, the quality of myocardial reperfusion in ST-segment elevation myocardial infarction was evaluated. Results: This study assessed 2,453 patients. The prescription rates of acetylsalicylic acid, p2y12 inhibitors, antithrombotic drugs, beta-blockers, angiotensin-converting enzyme inhibitors/IAT1RB, and statins were as follows: in 24 hours - 97.6%, 89.5%, 89.1%, 80.2%, 67.9% and 90.6%; and at six months - 89.3%, 53.6%, 0%, 74.4%, 57.6% and 85.4%, respectively. Regarding ST-segment elevation myocardial infarction, only 35.9% and 25.3% of the patients underwent primary angioplasty and thrombolysis, respectively, within the recommended times. Conclusion: This registry showed high initial prescription rates of antiplatelet drugs, antithrombotic drugs, and statins, and lower prescription rates of beta-blockers and angiotensin-converting enzyme inhibitors/IAT1RB. Independently of the class, the use of all drugs decreased by six months. Most patients with ST-segment elevation myocardial infarction did not undergo myocardial reperfusion within the time recommended. .